83
Participants
Start Date
August 31, 2016
Primary Completion Date
June 30, 2017
Study Completion Date
June 30, 2017
CSL_112
CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
Placebo
0.9% weight/volume sodium chloride solution (ie, normal saline)
Study Site 18001, Budapest
Study Site 18005, Budapest
Study Site 18007, Nyíregyháza
Study Site 18009, Szeged
Study Site 18003, Pécs
Study Site 17005, Berlin
Study Site 17009, Berlin
Study Site 19008, Safed
Study Site 17003, Berlin
Study Site 17006, Hamburg
Study Site 19002, Nahariya
Study Site 16056, Durham
Study Site 16014, High Point
Study Site 16003, Jacksonville
Study Site 16101, Birmingham
Study Site 16078, Huntsville
Study Site 16061, Petoskey
Study Site 16018, Rapid City
Study Site 17014, Frankfurt am Main
Study Site 16208, Alexandria
Study Site 16241, Wichita Falls
Study Site 17001, Freiburg im Breisgau
Study Site 16130, Littleton
Study Site 16112, Boise
Study Site 16168, Concord
Study Site 19005, Haifa
Study Site 16135, Danbury
Study Site 21001, Alkmaar
Study Site 21006, Amsterdam
Study Site 21017, Amsterfoort
Study Site 21008, Nijmegen
Lead Sponsor
CSL Behring
INDUSTRY